What’s Going On With BridgeBio Pharma Stock On Monday?

Monday, BridgeBio Pharma Inc (NASDAQ:BBIO) and Bayer AG (OTC:BAYRY) (OTC:BAYZF) announced a partnership wherein BridgeBio grants Bayer an exclusive license to commercialize acoramidis for ATTR-CM in Europe. 

In exchange, BridgeBio will receive up to $310 million, including upfront and near-term milestone payments and additional undisclosed sales milestones. 

BridgeBio will also receive royalties in a tiered structure beginning in the low-thirties percent on sales of acoramidis in Europe.

Related Content: Rare Disease Player BridgeBio …

Full story available on Benzinga.com